7-[(2-Amino-ethyl)amino]-1-ethyl-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid | 528851-28-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-[(2-Amino-ethyl)amino]-1-ethyl-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid
• 英文别名: 7-(2-aminoethylamino)-1-ethyl-4-oxoquinoline-3-carboxylic acid
• CAS: 528851-28-7
• 化学式: C₁₄H₁₇N₃O₃
• 分子量: 275.307
• InChiKey: GZMQXUOVIGTWPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.2
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  95.7
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4"-O-propenoyl-6-O-methyl-erythromycin A 、 7-[(2-Amino-ethyl)amino]-1-ethyl-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid 以 异丙醇 为溶剂， 生成 4''-O-[3-({2-[(3-carboxy-1,4-dihydro-1-ethyl-4-oxoquinolin-7-yl)amino]ethyl}amino)propanoyl]-6-O-methylerythromycin A
  参考文献：
  名称：

  4″-O-(ω-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens

  摘要：

  Four macrolides-6-O-methyl-8a-aza-8a-homoerythromycin, clarithromycin, azithromycin and azithromycin 11,12-cyclic carbonate, have been selected for the construction of a series of new quinolone derivatives. The quinolone moiety is connected to the macrolide scaffold via a diaminoaklyl 4"-O-propionyl ester chain of varying length. At the terminus the linker is attached via one of the nitrogen atoms in the linker at C(6) or C(7) of the quinolone. Many of compounds described, particularly clarithromycin derivative 37, and azithromycin derivatives 48 and 55, exhibited excellent antibacterial activity against a wide range of clinically relevant macrolide-resistant organisms, with profiles superior to that of telithromycin, an enhanced spectrum ketolide. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.06.049
• 作为产物：
  描述：

  诺氟沙星杂质3 、 乙二胺 、 二氯甲烷 以 N-甲基吡咯烷酮 、 甲醇 为溶剂， 反应 10.0h， 以to give the title compound (830 mg)的产率得到7-[(2-Amino-ethyl)amino]-1-ethyl-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid
  参考文献：
  名称：

  Macrolides

  摘要：

  本发明涉及在式(I)的第4位取代的14或15成员大环内酯及其药学上可接受的盐和溶剂化物，以及它们的制备方法和在人或动物体内治疗或预防系统性或局部细菌感染的用途。

  公开号：

  US20050080025A1

文献信息

• 14 OR 15 MEMBERED MACROLIDES WITH ANTIBACTERIAL ACTIVITY
  申请人：GLAXO GROUP LIMITED

  公开号：EP1453846B1

  公开（公告）日：2007-05-16
• US7202221B2
  申请人：——

  公开号：US7202221B2

  公开（公告）日：2007-04-10
• 4″-O-(ω-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens
  作者：A. Fajdetić、H. Čipčić Paljetak、G. Lazarevski、A. Hutinec、S. Alihodžić、M. Đerek、V. Štimac、D. Andreotti、V. Šunjić、J.M. Berge、S. Mutak、M. Dumić、S. Lociuro、D.J. Holmes、N. Maršić、V. Eraković Haber、R. Spaventi

  DOI：10.1016/j.bmc.2010.06.049

  日期：2010.9

  Four macrolides-6-O-methyl-8a-aza-8a-homoerythromycin, clarithromycin, azithromycin and azithromycin 11,12-cyclic carbonate, have been selected for the construction of a series of new quinolone derivatives. The quinolone moiety is connected to the macrolide scaffold via a diaminoaklyl 4"-O-propionyl ester chain of varying length. At the terminus the linker is attached via one of the nitrogen atoms in the linker at C(6) or C(7) of the quinolone. Many of compounds described, particularly clarithromycin derivative 37, and azithromycin derivatives 48 and 55, exhibited excellent antibacterial activity against a wide range of clinically relevant macrolide-resistant organisms, with profiles superior to that of telithromycin, an enhanced spectrum ketolide. (C) 2010 Elsevier Ltd. All rights reserved.
• Macrolides
  申请人：Alihodzic Suleman

  公开号：US20050080025A1

  公开（公告）日：2005-04-14

  The present invention relates to 14 or 15 membered macrolides substituted at the 4 th position of formula (I) and pharmaceutically acceptable salts and solvates thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body.

  本发明涉及在式(I)的第4位取代的14或15成员大环内酯及其药学上可接受的盐和溶剂化物，以及它们的制备方法和在人或动物体内治疗或预防系统性或局部细菌感染的用途。